Effect of Virtual Reality on Pain and Anxiety During Chemotherapy Session in Breast Cancer Patients
NCT ID: NCT07292727
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
50 participants
INTERVENTIONAL
2025-12-15
2026-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Anxiety is present in about 10% of people during chemotherapy, while one-third of people with depression also show clinically significant anxiety states.
Pain occurs in 90% of patients treated with chemotherapy. Pain includes that produced by the neurotoxic action of antiblastic drugs, mechanical pressure of the tumor mass, metastases and pain in the phantom limb.
Over the last two decades, virtual reality (VR), has shown efficacy as a distraction tool to alleviate pain and distress during medical procedures. The need of this study is developed from the lack in the quantitative knowledge and information in the published studies about the effect of virtual reality on pain and anxiety in cancer patient during chemotherapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Virtual reality group
This group includes patients suffered from pain and anxiety. The patients received their traditional care in addition to a fully immersive Head-Mounted Display virtual reality.
traditional care
Patients will take their prescribed medications from their physician and will continue their traditional activities during the intervention period, including reading, watching television, or visiting with guests.
Virtual reality
The patients will receive their traditional care in addition to a fully immersive Head-Mounted Display virtual reality (Oculus meta Quest virtual reality (VR) headset with hand controller ) for 30 minutes, starting from the patient's second chemotherapy session and last for 3 sessions.
Traditional care group
This group includes patients suffering from pain and anxiety. Patients will receive their traditional care at every chemotherapy session
traditional care
Patients will take their prescribed medications from their physician and will continue their traditional activities during the intervention period, including reading, watching television, or visiting with guests.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
traditional care
Patients will take their prescribed medications from their physician and will continue their traditional activities during the intervention period, including reading, watching television, or visiting with guests.
Virtual reality
The patients will receive their traditional care in addition to a fully immersive Head-Mounted Display virtual reality (Oculus meta Quest virtual reality (VR) headset with hand controller ) for 30 minutes, starting from the patient's second chemotherapy session and last for 3 sessions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who suffered from pain.
* Patient who suffered from anxiety.
* Patients who received chemo since 1cycle (session).
* Patients who received the same type of chemotherapy.
* Patients who are not suffer from anxiety disorders before chemotherapy.
* Patient who received chemotherapy for the first time in their treatment.
Exclusion Criteria
* injuries to the face or head
* Hand Injuries.
* Cognitive impairment
* A history of severe motion sickness
* Mental health problems.
* Visual and auditory problems.
* Radiotherapy
* A history of skull structure or cervical spine abnormalities that may complicate the use of VR devices.
* A history of epilepsy, seizures, vertigo.
30 Years
55 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hanaa Hassanin Shehata Hassan
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed Khalifa, Professor
Role: STUDY_DIRECTOR
Sohag University
Mohamed KhallafK, Professor
Role: STUDY_CHAIR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hanaa Hassanin Shehata
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P.T.REC/012/005460
Identifier Type: -
Identifier Source: org_study_id